Loading
Trials often require a fresh tumour biopsy just to enter, even when the sample is only for research. Classifying each biopsy as essential or research-only, making the latter optional and allowing blood tests or archived tissue for eligibility markers, would remove a painful hurdle that drives refusals.
Protocols classify each biopsy as essential (eligibility-defining, no alternative) or research-only; research-only biopsies become optional sub-studies, and eligibility biomarkers may be assessed on archival tissue or ctDNA where analytically validated. Screen-failure and refusal attributable to biopsy requirements are tracked and published.
Shares Foundation Medicine (Roche), Guardant Health, Comprehensive genomic profiling.
Shares Circulating tumour DNA (ctDNA), Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Foundation Medicine (Roche), Guardant Health, Trials enrol too few, too slowly, Comprehensive genomic profiling.
Shares Guardant Health, Circulating tumour DNA (ctDNA), Toxicity and quality of life are undervalued, Liquid biopsy (ctDNA).
Shares Trials enrol too few, too slowly, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Guardant Health, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).